4-溴-2-甲基喹啉 | 50488-44-3

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-溴-2-甲基喹啉
• 中文别名: 2-甲基-4-溴喹啉
• 英文名称: 4-Bromo-2-methylquinoline
• 英文别名: 4-Brom-2-methyl-chinolin
• CAS: 50488-44-3
• 化学式: C₁₀H₈BrN
• mdl: MFCD02278398
• 分子量: 222.084
• InChiKey: BGIRQGWGBRSRGK-UHFFFAOYSA-N

物化性质

• 沸点：
  88-90℃ (1 Torr)
• 密度：
  1.488±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2～8℃，干燥，密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-2-methylquinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-2-methylquinoline
CAS number: 50488-44-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H8BrN
Molecular weight: 222.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

4-溴-2-甲基喹啉属于喹啉类有机物，可用作医药中间体。有文献报道其可用于制备一类具有黄嘌呤氧化酶和URAT1双重抑制活性的羧酸取代的（杂）芳环类衍生物，如4-(2-氰基喹啉-4-基)-2-羟基苯甲酸。

制备

4-溴-2-甲基喹啉可由苯胺和乙酰乙酸乙酯为原料通过两步反应制备得到。

反应信息

• 作为反应物：
  描述：

  4-溴-2-甲基喹啉 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 2-甲基喹啉
  参考文献：
  名称：

  设计，合成和生物评价2-取代喹啉作为潜在的抗疟药

  摘要：

  为了确定潜在的候选药物治疗内脏利什曼病，合成了2-取代的喹啉化合物的类似物库。测试了这些分子对利什曼原虫的体外和体内生物活性。这些化合物的代谢稳定性也通过引入卤素取代基得到了改善。化合物（26g），被发现是最活跃的；IC 50值为0.2μM，选择性> 180倍。（26g）的盐酸盐在L. donovani中50 mg / kg×5天（每天两次，口服）剂量下显示84.26±4.44％的抑制作用/仓鼠模型。功效与观察到的PK数据高度相关，这表明该化合物分布均匀。

  DOI：

  10.1016/j.ejmech.2013.08.028
• 作为产物：
  描述：

  4-羟基-2-甲基喹啉 在 三溴化磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以16%的产率得到4-溴-2-甲基喹啉
  参考文献：
  名称：

  设计，合成和生物评价2-取代喹啉作为潜在的抗疟药

  摘要：

  为了确定潜在的候选药物治疗内脏利什曼病，合成了2-取代的喹啉化合物的类似物库。测试了这些分子对利什曼原虫的体外和体内生物活性。这些化合物的代谢稳定性也通过引入卤素取代基得到了改善。化合物（26g），被发现是最活跃的；IC 50值为0.2μM，选择性> 180倍。（26g）的盐酸盐在L. donovani中50 mg / kg×5天（每天两次，口服）剂量下显示84.26±4.44％的抑制作用/仓鼠模型。功效与观察到的PK数据高度相关，这表明该化合物分布均匀。

  DOI：

  10.1016/j.ejmech.2013.08.028

文献信息

• Efficient copper-catalyzed coupling of aryl chlorides, bromides and iodides with aqueous ammonia
  作者：Hanhui Xu、Christian Wolf

  DOI：10.1039/b904188e

  日期：——

  The copper(I)-catalyzed synthesis of a range of primary anilines from electron-rich and electron-deficient aryl halides including aryl chlorides has been achieved with aqueous ammonia, avoiding the need for inert atmosphere, expensive catalysts and ligands, anhydrous solvents, and additional base or other additives.

  用氨水可实现由富电子和缺电子的芳基卤化物（包括芳基氯化物）进行铜（Ⅰ）催化的一系列伯苯胺的合成，从而避免了惰性气氛，昂贵的催化剂和配体，无水溶剂和额外的碱或其他添加剂。
• [EN] CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF<br/>[FR] DÉRIVÉS DE CYCLE (HÉTÉRO) AROMATIQUE SUBSTITUÉS PAR CARBOXY ET PROCÉDÉS DE PRÉPARATION ET UTILISATIONS ASSOCIÉS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2017036404A1

  公开（公告）日：2017-03-09

  Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

  提供了含有羧基取代的(杂)芳基衍生物、包括这些化合物的药物组合物，以及制备这些化合物和组合物的方法。这些化合物或组合物在抑制黄嘌呤氧化酶和尿酸阴离子转运蛋白1方面具有用途，并且还可用于治疗或预防与高血尿酸水平有关的疾病，特别是人类。
• Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases
  申请人：——

  公开号：US20030229084A1

  公开（公告）日：2003-12-11

  The present application describes novel barbituric acid derivatives of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R 1 , R 2 , R 3 , R 4 , R 5 , n, W, U, X, Y, Z, U a , X a , Y a , and Z a are defined in the present specification, which are useful as TNF-&agr; converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.

  本申请描述了式I的新型巴比妥酸衍生物： 1 或其药用可接受的盐或前药形式，其中A、B、L、R 1 、R 2 、R 3 、R 4 、R 5 、n、W、U、X、Y、Z、U a 、X a 、Y a 和Z a 在本规范中定义，这些衍生物可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• Tandem Pd-Catalyzed Intermolecular Allylic Alkylation/Allylic Dearomatization Reaction of Benzoylmethyl pyridines, Pyrazines, and Quinolines
  作者：Hui-Jun Zhang、Ze-Peng Yang、Qing Gu、Shu-Li You

  DOI：10.1021/acs.orglett.9b01060

  日期：2019.5.3

  An efficient synthesis of nitrogen-containing heterocycles via Pd-catalyzed tandem allylic alkylation and dearomatization reactions was reported. In this reaction design, heteroarenes such as pyridines, pyrazines, and quinolines serve as bis-nucleophiles by installing a benzoyl group at the C2 benzylic position. With but-2-ene-1,4-diyl dimethyl dicarbonate as the bis-electrophile, the tandem Pd-catalyzed

  据报道，通过Pd催化的串联烯丙基烷基化和脱芳香化反应可有效合成含氮杂环。在该反应设计中，杂芳烃如吡啶，吡嗪和喹啉通过在C2苄基位置安装苯甲酰基而用作双亲核试剂。以二碳酸二烯丁酯-1,4-二烷基二芳酯为双亲电子体，已开发了串联的钯催化苯甲酰基甲基取代的杂芳烃的分子间烯丙基烷基化/烯丙基脱芳香化反应。以中等至良好的产率获得了2，3-二氢吲哚嗪，6，7-二氢吡咯并[1,2- a ]吡嗪和1，2-二氢吡咯并[1,2- a ]喹啉衍生物。
• Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20030139388A1

  公开（公告）日：2003-07-24

  The present application describes novel cyclic hydroxamic acids of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR 1 , and S(O) p , and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.

  本申请描述了新型的公式I:1的环式羟羧酸，或其药用盐形式，其中环B是一个包含0-2个来自O、N、NR1和S(O)p的杂原子以及0-1个羰基的5-7元环系统，其他变量在本说明书中有定义，这些化合物可作为基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶或其组合的抑制剂，包含这些化合物的药物组合物，以及使用这些化合物的方法。